MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1

Molecular Medicine Reports

Volumn 11, Issue 1, 2015, Pages 625-632

  Ma, Yanxin ^a,b   Li, Xuenan ^a   Cheng, Song ^a   Wei, Wei ^b   Li, Yaming ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Petrochina Daqing Oilfield   (China)

Author keywords

A549; ATP binding cassette; Diamminedichloroplatinum; Drug resistance; Member 1; MiR 106a; Sub family A

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER C9; ABC TRANSPORTER D2; ABC TRANSPORTER G4; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; MICRORNA; MICRORNA 106A; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 6; MULTIDRUG RESISTANCE PROTEIN 5; UNCLASSIFIED DRUG; MESSENGER RNA; PROTEIN ABCC9; ANTINEOPLASTIC AGENT; MIRN106 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; A549 CELL LINE; APOPTOSIS; ARTICLE; BINDING SITE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FLOW CYTOMETRY; GENE EXPRESSION; GENE IDENTIFICATION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION QUANTITATIVE POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CYTOTOXICITY; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; BIOLOGICAL MODEL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ATP BINDING CASSETTE TRANSPORTER 1; BASE SEQUENCE; BINDING SITES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; MODELS, BIOLOGICAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84916239832     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2688     Document Type: Article

References (31)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241, 2012.
2. Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907, 2010.
3. Saika K and Machii R: Cancer mortality attributable to tobacco by region based on the WHO Global Report. Jpn J Clin Oncol 42: 771-772, 2012.
4. Stinchcombe TE and West HL: Maintenance therapy in non-small-cell lung cancer. Lancet 374: 1398-1400, 2009.
5. Chang A: Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung cancer. 71: 3-10, 2011.
6. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004
7. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF and Pogribny IP: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152-2159, 2008.
8. Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M and Ju J: Molecular mechanism of chemoresi stance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 9: 96, 2010.
9. Hummel R, Hussey DJ and Haier J: MicroRNAs: predictors and modifers of chemo-and radiotherapy in different tumour types. Eur J Cancer 46: 298-311, 2010.
10. Huh JH, Kim TH, Kim K, Song JA, Jung YJ, Jeong JY, Lee MJ, Kim YK, Lee DH and An HJ: Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer 109: 452-461, 2013.
11. Wang PY, Li YJ, Zhang S, Li ZL, Yue Z, Xie N and Xie SY Regulating A549 cells growth by ASO inhibiting miRNA expression. Mol Cell Biochem 339: 163-171, 2010.
12. Locher KP: Structure and mechanism of ABC transporters. Curr Opin Struct Biol 14: 426-431, 2004
13. Iwasaki H, Okabe T, Takara K, Yoshida Y, Hanashiro K and Oku H: Down-regulation of lipids transporter ABCA1 increases the cytotoxicity of nitidine. Cancer Chemother Pharmacol 66: 953-959, 2010.
14. Borst P, Evers R, Kool M and Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295-1302, 2000.
15. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002.
16. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
17. Deeley RG and Cole SP: Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol 8: 193-204, 1997
18. Fang Y, Shen H, Li H et, al. miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim Biophys Sin (Shanghai). 2013. 45(11):963-72.
19. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, Su F, Yao H and Song E: Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 286: 19127-19137, 2011.
20. Suh SS, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ, Kim T, Bakàcs A, Alder H, Kaur B, et al: MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci USA 109: 5316-5321, 2012.
21. Dong Z, Zhong Z, Yang L, Wang S and Gong Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9 Cancer Lett 343: 249-257, 2014
22. Li Y, Li L, Guan Y, Liu X, Meng Q and Guo Q: MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN. Biochem Biophys Res Commun 440: 604-610, 2013.
23. Song L, Li Y, Li W, Wu S and Li Z: miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). J Cell Biochem 115: 1234-1242, 2014
24. Gillet JP, Efferth T and Remacle J: Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775: 237-262, 2007
25. Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ and Richardson DR: P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem 288: 31761-31771, 2013.
26. Dai DW, Lu Q, Wang LX, Zhao WY, Cao YQ, Li YN, Han GS, Liu JM and Yue ZJ: Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM. BMC Cancer 13: 478, 2013.
27. Liu Z, Gersbach E, Zhang X, Xu X, Dong R, Lee P, Liu J, Kong B, Shao C and Wei JJ: miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma. Mol Cancer Res 11: 1314-1325, 2013.
28. Zhi F, Zhou G, Shao N, Xia X, Shi Y, Wang Q, Zhang Y, Wang R, Xue L, Wang S, et al: miR-106a-5p inhibits the proliferation and migration of astrocytoma cells and promotes apoptosis by targeting FASTK. PLoS One 8: e72390, 2013.
29. Lee BH, Taylor MG, Robinet P, et al: Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. Cancer Res 73: 1211-1218, 2013.
30. Smith B and Land H: Anticancer activity of the cholesterol exporter ABCA1 gene. Cell Rep 2: 580-590, 2012.
31. Bachmeier BE, Iancu CM, Killian PH, Kronski E, Mirisola V, Angelini G, Jochum M, Nerlich AG and Pfeffer U: Overexpression of the ATP binding cassette gene ABCA1 determines resistance to Curcumin in M14 melanoma cells. Mol Cancer 8: 129, 2009.